5Fox I.P. Pathology and management o{ dermalologic toxicities associated with anti-E(}PR therapy [J]. Oneology (Williston Park) ,2006,20(5 Suppl 2):26 34.
6Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side effccts in cancer patients treated with the anficpiderma| growth factor receptor antibody C225[J]. Br J Dermatol. 2001,144(6) : 1169 1176.
8Zhang G, Basti S, Jampol I.M. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epi dermal growth factor receptor inhibitors: case reports and a re view of literature[J]. Cornea, 2(107,26 (7) : 858-8611.
9Carser .IE, Summers YJ. Trchomegay of te eyelashes af{ter treatment with erlotinib in non small cell lung cancer[J]. J Thorac Oncol,2006,1(9) : 1040 1041.
1Hidalgo M,Sin LL,Nemunaitis J' et al.Phase Ⅰ and pharmacologicstudy of OSI-774,anepidermal growth factor receptor tyrosine kiBase inhibitor,in patients with advanced solid malignancies[J].J Clin Oncol,2001,19(13):3267.
2Gamememr U.Pluzanska A.Results of aphase Ⅲ trial of edotimh(osi-7741 combined with cisplatin and gemcitabine(GC)chemo-therapy in advanced non-smaU cell lung cancer(NSCLC)[J].ProcAm Soc Clin Oncol,2004,22(14S):619S.
3Perez-Sohr R,Chechoua A.Determinants of tumor response and survival with erlotinib in patients with non-smaU-cell lung cancer[J].J Clin Oncol,2004,22 (16):3238.
7Demidem A,Lam T,Alas S.Chimeric anti-CD20(IDECC2B8)monoclonal antibody sensitizes a B celllymphoma cell line to cell killing by cytotoxic drugs[J].Cancer Biother Radiopharm,1997,12(3):177.
8Deshaies RJ.Drug discovery:fresh target for cancertherapy[J].Nature,2009,458(7 239):709.
9Miller AD.Modulation of vomiting by medullary midline[J].Brain Res,1996,737(1/2):51.
10Helikar T,Kochi N,Kowal B,et al.A comprehensive,multi-scale dynamical model of erb receptor signal transduction in human mammary epithelial cells[J].Plos One,2013,4(8):1.
